Patient with non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Part 2. Secondary prophylaxis

Non-cardioembolic ischemic stroke (IS) of high and very high risk includes three groups of patients: with severe extracranial atherosclerosis, with any intracranial atherosclerosis, and with aortic arch atheromatosis. This risk is also characteristic of patients with aggressive transient ischemic attack (TIA) phenotypes. Effectiveness of secondary prophylaxis can be raised by these strategies: short-term dual antiplatelet therapy using a combination of acetylsalicylic acid with clopidogrel or ticagrelor in minor IS or high-risk TIA; long-term dual antithrombotic therapy with acetylsalicylic acid and low doses of rivaroxaban for multifocal atherosclerosis with low hemorrhagic risk and non-lacunar stroke; early surgical revascularization (carotid endarterectomy or stenting) for non-disabling IS and urgent revascularization for high-risk TIA; intensive, including combined, lipid-lowering therapy with high doses of statins, ezetimibe, PCSK9 inhibitors, or inclisiran to achieve low-density lipoprotein levels <1.4 mmol/L ; antidiabetic therapy using type 2 glucose-sodium cotransporter inhibitors and type 1 glucagon-like peptide agonists with glycosylated hemoglobin level of <7%; prescribing antihypertensive therapy and achieving target blood pressure level.

1. Kulesh AA, Yanishevsky SN, Demin DA, et al. Patient with non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Part 1. Diagnosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):10-8. doi: 10.14412/2074-2711-2023-2-10-18 (In Russ.).

2. Wang Y, Wang Y, Zhao X, et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013 Jul 4;369(1):11-9. doi: 10.1056/NEJMoa1215340

3. Johnston SC, Easton JD, Farrant M, et al. Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19;379(3):215-25. doi: 10.1056/NEJMoa1800410

4. Johnston SC, Amarenco P, Denison H, et al. THALES Investigators. Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. N Engl J Med. 2020 Jul 16;383(3):207-17. doi: 10.1056/NEJMoa1916870

5. Krishnan K, Law ZK, Minhas JS, et al. Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician. Clin Med (Lond). 2022 Sep;22(5):449-54. doi: 10.7861/clinmed.20210597

6. Pan Y, Elm JJ, Li H, et al. Outcomes Associated With Clopidogrel-Aspirin Use in Minor Stroke or Transient Ischemic Attack: A Pooled Analysis of Clopidogrel in High-Risk Patients With Acute Non-Disabling Cerebrovascular Events (CHANCE) and Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trials. JAMA Neurol. 2019 Dec 1;76(12):1466-73. doi: 10.1001/jamaneurol.2019.2531

7. Amarenco P, Denison H, Evans SR, et al. THALES Steering Committee and Investigators*. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke. 2020 Dec;51(12):3504-13. doi: 10.1161/STROKEAHA.120.032239

8. Wang Y, Pan Y, Li H, et al. Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. Neurology. 2022 Jul 5;99(1):e46-e54. doi: 10.1212/WNL.0000000000200355

9. Dawson J, Merwick A, Webb A, et al. European Stroke Organisation. European Stroke Organisation expedited recommendation for the use of short-term dual antiplatelet therapy early after minor stroke and high-risk TIA. Eur Stroke J. 2021 Jun;6(2):VI. doi: 10.1177/23969873211027006

10. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467. doi: 10.1161/STR.0000000000000375

11. Amin HP, Madsen TE, Bravata DM, et al. American Heart Association Emergency Neurovascular Care Committee of the Stroke Council and Council on Peripheral Vascular Disease. Diagnosis, Workup, Risk Reduction of Transient Ischemic Attack in the Emergency Department Setting: A Scientific Statement from the American Heart Association. Stroke. 2023 Mar;54(3):e109-e121. doi: 10.1161/STR.0000000000000418. Epub 2023 Jan 19.

12. Eikelboom JW, Connolly SJ, Bosch J, et al. COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-30. doi: 10.1056/NEJMoa1709118

13. Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019 Feb 26;139(9):1134-45. doi: 10.1161/CIRCULATIONAHA.118.035864

14. Aboyans V, Bauersachs R, Mazzolai L, et al. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. Eur Heart J. 2021 Oct 14;42(39):4013-24. doi: 10.1093/eurheartj/ehab390

15. Dawson J, Bejot Y, Christensen LM, et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022 Sep;7(3):I-II. doi: 10.1177/23969873221100032

16. Arutyunov GP, Amelin AV, Voznyuk IA, et al. COMPASS study results as a foundation for new treatment approach for neurological patients. Opinion of the expert council of December 18, 2021. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2022;122(4):94-9. doi: 10.17116/jnevro202212204194 (In Russ.).

17. Psychogios M, Brehm A, Lopez-Cancio E, et al. European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease. Eur Stroke J. 2022 Sep;7(3):III-IV. doi: 10.1177/23969873221099715

18. Derdeyn CP, Chimowitz MI, Lynn MJ, et al. Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis Trial Investigators. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet. 2014 Jan 25;383(9914):333-41. doi: 10.1016/S01406736(13)62038-3

19. Ntaios G, Pearce LA, Meseguer E, et al. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke. 2019 Nov;50(11):3184-90. doi: 10.1161/STROKEAHA.119.025813

20. Hawkes MA, Braksick SA, Zhang W, et al. Can we stop the stuttering in stroke? Interventions in 40 patients with acute lacunes. J Neurol Sci. 2019 Jun 15;401:1-4. doi: 10.1016/j.jns.2019.04.009

21. Berberich A, Schneider C, Reiff T, et al. Dual Antiplatelet Therapy Improves Functional Outcome in Patients With Progressive Lacunar Strokes. Stroke. 2019 Apr;50(4):1007-9. doi: 10.1161/STROKEAHA.118.023789

22. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009 May;8(5):453-63. doi: 10.1016/S14744422(09)70058-4

23. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-37. doi: 10.1093/eurheartj/ehab484

24. Zeitouni M, Sabouret P, Kerneis M, et al. 2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):324-33. doi: 10.1093/ehjcvp/pvaa077

25. Voznyuk IA, Shamalov NA, Ezhov MV, et al. Optimization of lipid-lowering therapy in patients after ischemic stroke. Resolution of the Council of Experts. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2020;120(6):152-61. doi: 10.17116/jnevro2020120061152 (In Russ.).

26. Kukharchuk VV, Yezhov MV, Sergienko IV, et al. Diagnosis and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VII revision. Ateroskleroz i dislipidemii. 2020;1(38):7-42. doi: 10.34687/22198202.JAD.2020.01.0002 (In Russ.).

27. Averna M, Banach M, Bruckert E, et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021 May;325:99-109. doi: 10.1016/j.atherosclerosis.2021.03.039

28. Giugliano RP, Pedersen TR, Saver JL, et al. FOURIER Investigators. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke. 2020 May;51(5):1546-54. doi: 10.1161/STROKEAHA.119.027759

29. Khan SA, Naz A, Qamar Masood M, Shah R. Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia. Am J Cardiol. 2020 Nov1;134:69-73. doi: 10.1016/j.amjcard.2020.08.018

30. Hsu C, Saver JL, Ovbiagele B, et al. Association Between Magnitude of Differential Blood Pressure Reduction and Secondary Stroke Prevention: A Meta-analysis and Meta-Regression. JAMA Neurol. 2023 May 1;80(5):506-15. doi: 10.1001/jamaneurol.2023.0218

31. Dolui S, Detre JA, Gaussoin SA, et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral Blood Flow: Secondary Analysis of the SPRINT MIND Randomized Clinical Trial. JAMA Neurol. 2022 Apr 1;79(4):380-9. doi: 10.1001/jamaneurol.2022.0074

32. SPRINT MIND Investigators for the SPRINT Research Group; Nasrallah IM, Pajewski NM, Auchus AP, et al. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA. 2019 Aug 13;322(6):524-34. doi: 10.1001/jama.2019.10551

33. Nasrallah IM, Gaussoin SA, Pomponio R, et al. SPRINT Research Group. Association of Intensive vs Standard Blood Pressure Control with Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial. JAMA Neurol. 2021 May 1;78(5):568-77. doi: 10.1001/jamaneurol.2021.0178

34. Paciaroni M, Agnelli G, Caso V, et al. Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. Cerebrovasc Dis. 2009;28(2):119-23. doi: 10.1159/000223436. Epub 2009 Jun 5.

35. Staszewski J, Brodacki B, Kotowicz J, Stepien A. Intravenous insulin therapy in the maintenance of strict glycemic control in nondiabetic acute stroke patients with mild hyperglycemia. J Stroke Cerebrovasc Dis. 2011 Mar-Apr;20(2):150-4. doi: 10.1016/j.jstrokecerebrovasdis.2009.11.013. Epub 2010 Jul 10.

36. Rosso C, Corvol JC, Pires C, et al. Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial. Stroke. 2012 Sep;43(9):2343-9. doi: 10.1161/STROKEAHA.112.657122. Epub 2012 Jun 14.

37. Johnston KC, Bruno A, Pauls Q, et al. Intensive vs Standard Treatment of Hyperglycemia and Functional Outcome in Patients With Acute Ischemic Stroke: The SHINE Randomized Clinical Trial. JAMA. 2019 Jul 23;322(4):326-35. doi: 10.1001/jama.2019.9346

38. Shou J, Zhou L, Zhu S, Zhang X. Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis. J Stroke Cerebrovasc Dis. 2015;24:1961-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.04.004

39. Cosentino F, Grant PJ, Aboyans V, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi: 10.1093/eurheartj/ehz486

40. American Diabetes Association Professional Practice Committee; Draznin B, Aroda VR, Bakris G, et al. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S125-S143. doi: 10.2337/dc22S009

41. Joseph JJ, Deedwania P, Acharya T, et al. American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation. 2022 Mar;145(9):e722e759. doi: 10.1161/CIR.0000000000001040

42. Naylor R, Rantner B, Ancetti S, et al. European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2022 May 20:S1078-5884(22)00237-4. doi: 10.1016/j.ejvs.2022.04.011

43. Bonati LH, Kakkos S, Berkefeld J, et al. European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis. Eur Stroke J. 2021 Jun;6(2):IXLVII. doi: 10.1177/23969873211012121

44. Eriksson H, Koskinen S, Nuotio K, et al. Predictive Factors for Pre-operative Recurrence of Cerebrovascular Symptoms in Symptomatic Carotid Stenosis. Eur J Vasc Endovasc Surg. 2020 Dec;60(6):809-15. doi: 10.1016/j.ejvs.2020.08.044

45. Cui CL, Dakour-Aridi H, Lu JJ, et al. In-Hospital Outcomes of Urgent, Early, or Late Revascularization for Symptomatic Carotid Artery Stenosis. Stroke. 2022 Jan;53(1):100-7. doi: 10.1161/STROKEAHA.120.032410

46. Chernyavsky MA, Irtyuga OB, Yanishevsky SN, et al. Russian consensus statement on the diagnosis and treatment of patients with carotid stenosis. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2022;27(11):5284. doi:10.15829/1560-40712022-5284 (In Russ.).

47. Gao P, Wang T, Wang D, et al. CASSISS Trial Investigators. Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis: The CASSISS Randomized Clinical Trial. JAMA. 2022 Aug 9;328(6):534-42. doi: 10.1001/jama.2022.12000

48. Turan TN, Zaidat OO, Gronseth GS, et al. Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee. Neurology. 2022 Mar 22;98(12):486-98. doi: 10.1212/WNL.0000000000200030